Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

Clin Infect Dis. 2006 Jul 1;43(1):99-102. doi: 10.1086/504874. Epub 2006 May 26.

Abstract

Abacavir therapy is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allele. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects*
  • Australia
  • Cohort Studies
  • Dideoxynucleosides / adverse effects*
  • Drug Hypersensitivity / epidemiology
  • Drug Hypersensitivity / genetics*
  • Drug Hypersensitivity / prevention & control
  • Female
  • Genetic Testing
  • HIV Infections / drug therapy*
  • HLA-B Antigens / genetics*
  • Humans
  • Incidence
  • Male
  • Middle Aged

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • HLA-B Antigens
  • HLA-B*57:01 antigen
  • abacavir